Kress HG - Search Results

1

Cannabinoid receptor-independent suppression of the superoxide generation of human neutrophils (PMN) by CP55 940, but not by anandamide.

Kraft B, Wintersberger W, Kress HG. Kraft B, et al. Among authors: kress hg. Life Sci. 2004 Jul 9;75(8):969-77. doi: 10.1016/j.lfs.2004.02.007. Life Sci. 2004. PMID: 15193957

2

Indirect CB2 receptor and mediator-dependent stimulation of human whole-blood neutrophils by exogenous and endogenous cannabinoids.

Kraft B, Kress HG. Kraft B, et al. Among authors: kress hg. J Pharmacol Exp Ther. 2005 Nov;315(2):641-7. doi: 10.1124/jpet.105.084269. Epub 2005 Jul 29. J Pharmacol Exp Ther. 2005. PMID: 16055676

3

[Cannabinoids and the immune system. Of men, mice and cells].

Kraft B, Kress HG. Kraft B, et al. Among authors: kress hg. Schmerz. 2004 Jun;18(3):203-10. doi: 10.1007/s00482-003-0245-7. Schmerz. 2004. PMID: 15221424 Review. German.

4

The procoagulatory effects of delta-9-tetrahydrocannabinol in human platelets.

Deusch E, Kress HG, Kraft B, Kozek-Langenecker SA. Deusch E, et al. Among authors: kress hg. Anesth Analg. 2004 Oct;99(4):1127-1130. doi: 10.1213/01.ANE.0000131505.03006.74. Anesth Analg. 2004. PMID: 15385362

5

No evidence for direct modulatory effects of delta 9-tetrahydrocannabinol on human polymorphonuclear leukocytes.

Deusch E, Kraft B, Nahlik G, Weigl L, Hohenegger M, Kress HG. Deusch E, et al. Among authors: kress hg. J Neuroimmunol. 2003 Aug;141(1-2):99-103. doi: 10.1016/s0165-5728(03)00259-5. J Neuroimmunol. 2003. PMID: 12965259

6

Opioid medication and driving ability.

Kress HG, Kraft B. Kress HG, et al. Eur J Pain. 2005 Apr;9(2):141-4. doi: 10.1016/j.ejpain.2004.05.010. Eur J Pain. 2005. PMID: 15737803 Review.

7

Lack of analgesia by oral standardized cannabis extract on acute inflammatory pain and hyperalgesia in volunteers.

Kraft B, Frickey NA, Kaufmann RM, Reif M, Frey R, Gustorff B, Kress HG. Kraft B, et al. Among authors: kress hg. Anesthesiology. 2008 Jul;109(1):101-10. doi: 10.1097/ALN.0b013e31817881e1. Anesthesiology. 2008. PMID: 18580179 Clinical Trial.

8

No carnitine palmitoyltransferase deficiency in skeletal muscle in 18 malignant hyperthermia susceptible individuals.

Wieser T, Kraft B, Kress HG. Wieser T, et al. Among authors: kress hg. Neuromuscul Disord. 2008 Jun;18(6):471-4. doi: 10.1016/j.nmd.2008.03.007. Epub 2008 Apr 21. Neuromuscul Disord. 2008. PMID: 18430572

9

3,5-Di-t-butyl catechol is a potent human ryanodine receptor 1 activator, not suitable for the diagnosis of malignant hyperthermia susceptibility.

Lacava C, Michalek-Sauberer A, Kraft B, Sgaragli G, Sipos E, Höller C, Kress HG, Fusi F, Weigl LG. Lacava C, et al. Among authors: kress hg. Pharmacol Res. 2012 Jul;66(1):80-7. doi: 10.1016/j.phrs.2012.03.012. Epub 2012 Mar 28. Pharmacol Res. 2012. PMID: 22480578

10

Novel double and single ryanodine receptor 1 variants in two Austrian malignant hyperthermia families.

Kaufmann A, Kraft B, Michalek-Sauberer A, Weindlmayr M, Kress HG, Steinboeck F, Weigl LG. Kaufmann A, et al. Among authors: kress hg. Anesth Analg. 2012 May;114(5):1017-25. doi: 10.1213/ANE.0b013e31824a95ad. Epub 2012 Mar 13. Anesth Analg. 2012. PMID: 22415532

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

142 results

Search Page

Filters